• Previous and ongoing clinical trials

  2019-12-28

  

  Previous and ongoing clinical trials have been summarized in a recent review (Siaw-Debrah et al., 2017). To our knowledge, there are no ongoing or completed clinical trials focusing on cytokines in ICH. Published studies have focused mainly on cytokine changes in ICH patients (summarized in Table 3)

• notch pathway br Conflicts of interest br

  2019-12-28

  

  Conflicts of interest Acknowledgments Work in the laboratory of SPS is funded by Council of Scientific and Industrial Research (CSIR) Network Project BSC-0111 (INDEPTH) and BSC-0112 (NanoSHE). We are thankful to Director, CSIR-IITR for his constant encouragement and support. We also acknowledg

• Vatalanib Several single nucleotide polymorphisms SNPs

  2019-12-28

  

  Several single nucleotide polymorphisms (SNPs) in humans affect CYP3A expression and activity (Lamba et al., 2002). The CYP3A4 SNP rs2740574 (also referred to as CYP3A4*1B, by The Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/) is a change in the promoter regi

• br Making the BN Cox model computationally efficient

  2019-12-28

  

  Making the BN-Cox model computationally efficient One of the challenges to applying the BN-Cox model is an exponential growth of the conditional probability tables (CPT) corresponding to the survival variables, as the number of risk factors increases [22]. When the number of risk factors is high

• A French cohort study reported that

  2019-12-28

  

  A French cohort study reported that micronized progesterone or didrogesterone used with oral or percutaneous estradiol showed no increase or decrease in the risk of breast cancer compared to synthetic progestins for at least 4 years of treatment [22] and even after 8 years [23]. Although the results

• Other studies have investigated the role of HDAC

  2019-12-28

  

  Other studies have investigated the role of HDAC inhibitors in particular signaling pathways mediated by EWS–FLI1 (Matsumoto et al., 2001). A recent investigation, showed a physical association of EWS–FLI1 and HDAC1 that helps mediate a disruption in the p53 activation of downstream targets (Li et a

• A major open question in the field

  2019-12-28

  

  A major open question in the field of lipid mediators is the molecular nature of the PLA2 enzyme involved in the release of DHA and related omega-3 fatty acids from phospholipids as a first committed step for the generation of SPMs. Although by analogy with AA it is often assumed that cPLA2α may ser

• Therefore HNE is an attractive therapeutic target and the de

  2019-12-28

  

  Therefore, HNE is an attractive therapeutic target and the design of new HNE inhibitors is a demanding field that has been extensively investigated in order to provide inhibitors with new molecular architectures, including the potent oxo-β-lactam class [14]. In the present work, a coumarin-based oxo

• The inhibition of mRFP Ub E formation

  2019-12-27

  

  The inhibition of mRFP-Ub–E1 formation by ginsenosides Re was not in time-dependent in vitro (Fig. 4B). Fifty micrometres ginsenoside Rg1 decreased E1 activity to 0.24- to 0.36-fold over 30min. This finding suggests that ginsenoside Rg1 may irreversibly inhibit mRFP-Ub–E1 formation or a tight-bindin

• br Materials and methods br Results

  2019-12-27

  

  Materials and methods Results Discussion In this study we characterized in more detail the interrelationship between the expression levels of the B. malayi Bm-cpl-3 and Bm-cpl-6 cysteine proteases and the fitness of Wolbachia, and consequently that of the parasite. Our present in vitro data

• br Genotype phenotype correlations Genotype phenotype correl

  2019-12-27

  

  Genotype-phenotype correlations Genotype-phenotype correlations are limited. Compared with individuals with truncating variants, those with pathogenic missense variants in the adenosine triphosphate binding site had a milder disorder, some with ability to walk unaided, better hand use, and less r

• One of the therapeutic proteins used in cancer therapy is

  2019-12-27

  

  One of the therapeutic proteins used in cancer therapy is glucarpidase, also known as Carboxypeptidase G2, CPG2, which originates from the bacterium Variovorax paradoxus (old name, Pseudomonas sp. strain RS-16). It has no mammalian equivalent (Thompson et al., 1994; Kamlage, 1994) and is a zinc-depe

• br Disclosures br Introduction The

  2019-12-27

  

  Disclosures Introduction The presence of anti-viral T-cell immunity is crucial for effective and sustained protection against Cytomegalovirus (CMV) following allogeneic stem cell transplantation (alloSCT) [1]. In vitro and in vivo T-cell depletion (TCD) via addition of the anti-CD52 monoclonal

• br Conflicts of interest br Acknowledgements This work

  2019-12-27

  

  Conflicts of interest Acknowledgements This work was supported, in part or in whole, by the grants from the National Natural Science Foundation of China (11802056, 11772088), the China Postdoctoral Science Foundation (2018M640904), and the Fundamental Research Funds for the Central Universitie

• To our knowledge this is the first report of

  2019-12-27

  

  To our knowledge, this is the first report of an oncocytoma expressing alpha-enolase or causing autoimmune retinopathy and optic neuropathy. Although generally considered benign, oncocytomas have rarely been associated with paraneoplastic syndromes, including tumor-induced hypertension, erythrocytos

15157 records 852/1011 page Previous Next First page 上5页 851852853854855 下5页 Last page